AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04622644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: clinical investigation microwave device class IIa not marked CE for stroke detection
Description: Patients with hyperacute stroke are referred to the emergency room with a 'stroke code'. Clinical collected data includes NIHSS and mRS. Patients will undergo to NCCT in order to exclude the haemorragic nature of vascular disease. In the same diagnostic session the patient undergo to CTA with tri-phase protocol to assess LVO. Before starting the CTA acquisition with iodinate contrast injection the StrokeWave will be placed on the head of the patients in the CT room passing toward the gantry of the CT avoiding any loose of time. The scanning with the StrokeWave will be performed in about 5 minutes and the system will be removed allowing the CTA acquisition.
Study NCT05054257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CAR19 T lymphocytes
Description: First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL
Study NCT05688397 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental 1
Description: L. gasseri oral capsule once a day (1 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
Study NCT05688397 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental 2
Description: L. gasseri and L. crispatus oral capsule once a day (1.5 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
Study NCT05688397 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
Study NCT05246696 — intervention group
Intervention type: OTHER
Intervention: BodyBabe questionnaire
Description: assessment of young mothers' perceptions using self-questionnaires
Study NCT03543852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SurvivorLink
Description: SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
Study NCT05405270 — intervention group
Intervention type: DRUG
Intervention: Imiquimod
Description: Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.
Study NCT05405270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3x vaginal swab for microbiome analysis
Description: A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.
Study NCT05405270 — intervention group
Intervention type: OTHER
Intervention: Expectative management
Description: Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
Study NCT05357859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: solubilized vitamin D3
Description: solubilized vitamin D3
Study NCT05452681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive Y-AMBIENT
Study NCT05405270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2x vaginal swab for microbiome analysis
Description: A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
Study NCT05452681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05452681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04744103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCA
Description: Patients will receive a TCA peel as a treatment for their actinic cheilitis.
Study NCT05010473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech and non-speech sound stimulation
Description: Listening to repetitive and extended sound presentation induces specific neural and physiological activity that we will measure via electroencephalography and pupillometry
Study NCT05452681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05452681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05452681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Receive cookbook and socialization calls
Study NCT06425783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warmed Blood Transfusion
Description: The erythrocyte suspension will be heated between 34-36 C⁰, which is the determined physiological temperature.~Before giving it to the baby, 2 ml of blood will be taken through a triple tap and its hematocrit and K value (blood gas) will be checked. It will be given to the baby after the temperature is checked with a body fluid thermometer and determined to be within the appropriate range and if hemolysis is not observed.~At the end of the standard transfusion period of 3 hours, all babies will be routinely checked for blood gases, HTC and K.
Study NCT04943861 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weCare/Secure
Description: The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
Study NCT04943861 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: There is no peer navigation within usual care.
Study NCT05357859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: medium chain triglyceride
Description: MCT with same amount
Study NCT04890821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI Percutaneous Ring Annuloplasty System
Description: Percutaneous transcatheter implant and adjustment of the CI ring annuloplasty system.
Study NCT04861961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DS vs. SADI-S vs. OAGBP
Description: Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.
Study NCT06227702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid management according to Venous Excess Ultrasound (VExUS) Score
Description: Management of furosemide intravenous infusion according to VeXus results
Study NCT06330662 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Testing the effectiveness of hyaluronic acid in experimental group using a coronally advanced flap compared to a control group using a coronally advanced flap only
Description: The potential benefit of adding hyaluronic acid (HA) to the coronally advanced flap (CAF) operative technique to cover multiple adjacent recessions has not been sufficiently investigated. Improving aesthetics is one of the primary goals of root recession coverage periodontal surgery, and little is known about the same in multiple adjacent gingival recession coverage therapy. In patients with a sufficient amount (≥2 mm) of keratinized tissue, the coronally advanced flap (CAF) has been shown to be very effective in the treatment of multiple recessions, especially in terms of aesthetic results. The researchers concluded from a database search (Epistemonikos, Cochrane, Medline) that there is no evidence to support the use of HA + CAF to achieve greater root coverage in the treatment of multiple gingival recessions.
Study NCT06330662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testing the effectiveness of hyaluronic acid in experimental group using a coronally advanced flap compared to a control group using a coronally advanced flap only
Description: The potential benefit of adding hyaluronic acid (HA) to the coronally advanced flap (CAF) operative technique to cover multiple adjacent recessions has not been sufficiently investigated. Improving aesthetics is one of the primary goals of root recession coverage periodontal surgery, and little is known about the same in multiple adjacent gingival recession coverage therapy. In patients with a sufficient amount (≥2 mm) of keratinized tissue, the coronally advanced flap (CAF) has been shown to be very effective in the treatment of multiple recessions, especially in terms of aesthetic results. The researchers concluded from a database search (Epistemonikos, Cochrane, Medline) that there is no evidence to support the use of HA + CAF to achieve greater root coverage in the treatment of multiple gingival recessions.
Study NCT04713566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral rinces
Description: natural and commercial oral rinses were compared for efficacy
Study NCT05744115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-PSMA-11
Description: Ga-68-PSMA-11 is produced via a lyophilized Sterile Cold kit. Ga-68 is eluted from a Ge-68/Ga-68 generator into a vial containing the premixed peptide and buffer. PSMA-11 radiolabeled with Ga-68 is administered to patients following verification of standard quality controls including activity measurement, pH, radiochemical purity, and visual inspection
Study NCT05032326 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Follow-up study of the treated cohort
Description: follow-up study of the patients in the treated cohort: that have been included in the otbb3 study
Study NCT05766605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study NCT05766605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study NCT05766605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study NCT05766605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: 50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study NCT05766605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg per square body surface area was used for monthly transhepatic arterial infusions.
Study NCT05032326 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up study of the untreated cohort
Description: follow-up study of the patients in the untreated cohort: that have NOT been included in the otbb3 study
Study NCT06083402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HyaCera™
Description: 1 Ritual HyaCera capsule once daily
Study NCT06083402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule once daily
Study NCT05650177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blended Mindfulness-Based Intervention (bMBI)
Description: The blended Mindfulness-Based Intervention (bMBI) is a 24-week online course 'blended' with therapist support via video link. The entire course is completed online and requires no in person contact. The bMBI follows the general structure of Mindfulness-Based Cognitive Therapy (MBCT) with an added emphasis on the cultivation of self-compassion. The bMBI comprises of 9-themed sessions spread out over the 24-weeks. Each session involves: video instructions, written information, psycho-educational exercises, and guided meditation practices. Participants meditate for 30-minutes each day. Additional homework involves short daily activities designed to incorporate mindfulness into daily life and keeping a journal about experiences within and around the practices and exercises. The therapist sessions are every two weeks and last for 45-minutes and help participants overcome any problems they experience.
Study NCT04908280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.
Study NCT04741230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gebauer Lenticule
Description: The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.
Study NCT05896215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNP2002
Description: Dairy topical administration for 12 weeks
Study NCT05896215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of KNP2002
Description: Dairy topical administration for 12 weeks
Study NCT05171894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemopfin+Green Light
Description: All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.
Study NCT05171894 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle+Green Light
Description: All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.
Study NCT05506592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dermatological product
Description: cosmetic shampoo
Study NCT05506592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dermatological product
Description: cosmetic shampoo
Study NCT04520516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active VAGUSTIM device
Description: Settings: 25 Hz stimulation, 100 microsec pulse width, intensity escalation up to 8 mA or below if tingling sensation, 20 min/day of stimulation in one daily session
Study NCT04520516 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VAGUSTIM device
Description: The sham device : no electrical signal for VNS will be delivered.
Study NCT05401227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine during an MRI
Study NCT05401227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine during an MRI
Study NCT05401227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ts-134
Description: 4 days of TS-134 20 mg
Study NCT05401227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 days of placebo TS-134
Study NCT05459389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: targeted antibiotics therapy
Description: targeted antibiotics therapy guided by resistance genotyping (n=24)
Study NCT04912037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial intelligence assistance system
Description: the artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed, and feedback the overspeed percentage.
Study NCT05792670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Changing mechanic ventilatation parameters
Description: The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg. Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
Study NCT05014516 — intervention group
Intervention type: DRUG
Intervention: 129Xenon gas
Description: Observational
Study NCT04894786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Internal Rotation Mobilization
Description: Mulligan Internal Rotation Mobilization (MIRM) Sleeper Stretch The therapist places a web of his one hand around patient's axilla and thumb of another hand in the bent elbow and the glide will be applied to the head of the humerus down in the glenoid fossa using thumb while stabilizing the scapula with another hand. Therapist will ensures that the other hand is stabilizing up and inwards. While this distraction is taking place the patient internally rotated his shoulder with the help of another hand, at the same time his affected upper arm will abduct by therapist abdomen distracting the head of the humerus laterally. The hand in axilla acts as a fulcrum. Mulligan MWM will be applied for 3 days alternate days by following the rule of 3
Study NCT06412601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RPM
Description: remote patient monitoring by clinic staff
Study NCT06412601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: app
Description: use of Happy Bob phone app
Study NCT06412601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: app
Description: use of Happy Bob phone app
Study NCT04894786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Isometric Relaxation Technique
Description: Post Isometric Relaxation Technique (PIRT) Sleeper Stretch The subject will be positioned supine on the treatment table with the shoulder and elbow, at 90 degree of abduction and flexion. The shoulder will be stabilized at the acromion process with one hand, and the other hand will be used to passively move the arm into internal rotation until the first barrier of motion will reached. The subject will be then instructed to perform a 5second isometric contraction of approximately 25% maximal effort in the direction of external rotation, against an opposing force provided at the distal forearm. Following the contraction, the subject will be instructed to internally rotate the arm toward the ground as a 30-second active assisted stretch will be applied. The subject will be instructed to relax, and a new movement barrier will then engage.
Study NCT06117800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TeamSTEPPS
Description: Team Tools and Strategies to Enhance Performance and Patient Safety (TeamSTEPPS®) is an evidence-based framework that has been used in interprofessional education programs to develop and train newly graduate nurses to deal with difficult clinical situations.
Study NCT06121336 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma levels of BD-tau
Description: Plasma levels of BD-tau will be assessed using a single-molecule array assay.
Study NCT05582811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Riociguat 2,5 or 5mg
Description: A selective stimulator of soluble guanylate cyclase (sGC)
Study NCT05582811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: A selective stimulator of soluble guanylate cyclase (sGC)
Study NCT05582811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04827914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: Smokers in the enhanced care group will receive live counseling (either in person or telehealth consult) while hospitalized combined with post-hospital discharge automated calls using interactive voice recognition (IVR) technology.
Study NCT04827914 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Care
Description: Smokers assigned to the basic care group will only receive the post-discharge IVR phone calls.
Study NCT06566079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM6331
Description: Dosage form: Capsule for oral administration.~Frequency of administration: Once daily overall of treatment.
Study NCT06089954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: private web-portal eHealth disclosure of genetic results
Description: The intervention involves delivering actionable genetic research results to participants via a secure, private web-portal.
Study NCT05766605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Leucovorin, fluorouracil
Description: Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions
Study NCT05766605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin, Raltitrexed
Description: Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Study NCT06584812 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tiprogrel
Description: Period 1: Dose 1 Tiprogrel, loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
Study NCT06584812 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tiprogrel
Description: Period 2: Dose 2 Tiprogrel ; loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
Study NCT06584812 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Period 3: Clopidogrel; loading dose of Clopidogrel followed by daily maintenance dose until Day 8.